Tesamorelin Compound Reference
Published · Last updated · Publisher: ENOS Labs USA
What is Tesamorelin?
Tesamorelin is a stabilized analog of the 44 residue growth hormone releasing hormone. As Egrifta it is FDA approved for one indication: reducing excess abdominal fat in adults with HIV associated lipodystrophy. That approval rests on phase 3 trials. Research grade tesamorelin is not the approved drug product and has no other approved use.
- Synonyms
- TH9507; Egrifta (approved drug product)
- Classification
- Synthetic analog of full length growth hormone releasing hormone (GHRH 1-44)
What is Tesamorelin?
Tesamorelin adds a trans-3-hexenoyl group to the N terminus of GHRH(1-44), which protects it from rapid enzymatic breakdown.
Research context
Phase 3 trials in HIV associated lipodystrophy were published from 2007, with later studies of liver fat and fat quality in people with HIV.
Mechanisms being investigated
- GHRH receptor activation, increasing pulsatile growth hormone release and downstream IGF-1.
Research status
Approval status: FDA approved (limited indication). Highest evidence tier in the cited literature: clinical trials.
FDA approved (Egrifta) for reduction of excess abdominal fat in HIV associated lipodystrophy. Not approved for any other use.
Established findings
- Efficacy on visceral fat in HIV associated lipodystrophy from randomized trials.
- Its regulatory approval for that single indication.
Preliminary or experimental findings
- Effects in other populations, including cognition studies, which are investigational.
Chemical reference information
| Molecular formula | C221H366N72O67S |
|---|---|
| Molecular weight | 5136 g/mol |
| CAS number | 218949-48-5 |
| PubChem CID | 16137828 |
Values taken from the PubChem record.
Testing considerations
- Large 44 residue peptide: high resolution MS and a well resolved HPLC method are needed to separate closely related impurities.
General methods are explained in purity versus identity testing.
What is still unknown
- Long term effects outside the approved population.
Related resources
ENOS catalog listing: Tesamorelin 10MG
Research use limitations
This page summarizes published research and regulatory status. It is not medical advice and does not describe any use in people. Material supplied by ENOS Labs USA is for in-vitro laboratory research only and is not a drug product, even where a related drug has been approved.
To continue, see recovery and performance research, how to read a certificate of analysis, why purity and identity are separate tests, the compound directory and the peptide testing glossary.
References
Each source below was opened and checked against its PubMed, ClinicalTrials.gov or PubChem record. Links open in a new tab.
- Metabolic effects of a growth hormone-releasing factor in patients with HIV (PMID 18057338)The New England Journal of Medicine, 2007 · PubMed
- Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy (PMID 21668043)Drugs, 2011 · PubMed
- TH9507 in Patients With HIV-Associated Lipodystrophy (NCT00435136)ClinicalTrials.gov · NIH National Library of Medicine
- Tesamorelin compound record (PubChem CID 16137828)PubChem · NIH National Library of Medicine
These products are sold strictly for in-vitro laboratory research and are not intended for human consumption, diagnosis, treatment, or any therapeutic use. Purchaser must be 18 years of age or older and confirms they are a qualified researcher.